Reportlinker Adds Advanced Lung Cancer in Patient Smoker with Squamous Cell: Clinical Insights from a US Oncologists' Survey

NEW YORK, April 28, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0487248/Advanced-Lung-Cancer-in-Patient-Smoker-with-Squamous-Cell-Clinical-Insights-from-a-US-Oncologists-Survey.html

Advanced Lung Cancer in Patient Smoker with Squamous Cell: Clinical Insights from a US Oncologists' Survey

A patient specific case scenario on advanced lung cancer in a situation involving a smoker with squamous cell that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progression reveals:

• Decisions in treatment and tests through disease stages

• Factors influencing their decisions

• Barriers to optimal care

• Confidence in treatment.

Data has been synthesized to show all responses and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on Advanced Lung Cancer.

Treatment decisions for advanced stages of breast cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists' choices. This report is part of a series of oncology reports that allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.

This report allows you to:

• Understand what occurs with actual patients

• Access the most up-to-date prescribing trends

• Gain actionable data for developing and improving your market strategies

• Pinpoint needs of your target audience

• Focus resources to maximize the effectiveness of your budget

• Understand where your product fits

• Understand where your competitor's product fits

• Design messages to advance brand performance

Table of Contents

Executive Summary5

Chapter 1: Introduction7

Table 1: Treatment Options in Advanced Lung Cancer7

Chapter 2: Respondent Demographics9

Table 2: Eligibility Criteria for Survey Participation9

Figure 2.1 Gender of Survey Respondents9

Figure 2.2 Years since Medical School Graduation10

Figure 2.3 Practice Settings10

Figure 2.4 Practices in NCI Cancer Centers11

Figure 2.5 Geographic Settings11

Figure 2.6 Survey Respondents by State's Lung Cancer Mortality12

Figure 2.7 Number of Physicians in Practice Groups13

Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen13

Chapter 3: Treatment of a Smoker with Squamous Cell Carcinoma14

Figure 3.1 Laboratory studies to be done on the tumor tissue14

Figure 3.2 First line chemotherapy regimen15

Figure 3.3 Factors Influencing Treatment Decisions16

Figure 3.4 Confidence in treating this patient to an optimal outcome18

Figure 3.5 Next step in management19

Figure 3.6 Subsequent treatment regimen21

Figure 3.7 Treatment at next cancer progression22

Figure 3.8 Factors influencing treatment decisions23

Figure 3.9 Barriers to management of advanced lung cancer25

Chapter 4: Summary27

Appendix A: Survey Instrument29

Companies mentioned

Eli Lilly, Genentech/Roche, Bristol-Myers Squibb, Glaxo Smith Kline, Pfizer, Sanofi-aventis

To order this report:

:

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.